David Lehmann

This inventor holds 15 USPTO granted patents, plus 2 CIPO patents and 10 EPO patents, primarily in Immunomodulating Agents. Top assignees: Actelion Pharmaceuticals Ltd, Other. Active years: 2009-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Lehmann. Retrieved from https://idiyas.com/inventor/david-lehmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15

% Patents Active = 20.0

CIPO Patents = 2

EPO Patents = 10 (Patent Applications = 1)

Average Co-Inventor Count = 6.9

ph-index = 8

Forward Citations = 121(Granted Patents)

Location History:

Galmiz, CH (2011 - 2013)
Basel, CH (2009 - 2014)
Allschwil, CH (2014)

Company Filing History:

14 out of 217

Actelion Pharmaceuticals Ltd

patents

1 out of 834,659

Other

patents

Years Active: 2009-2014

Loading Chart...

Areas of Expertise:

Pyridine Derivatives

Thiazole Derivatives

P2Y12 Receptor Antagonists

Immunomodulating Agents

Thiophene Derivatives

S1P1 Receptor Agonists

Phenyl Derivatives

Hydrogenated Benzo Thiophene

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8697732 - Pyridine derivatives (2014-04-15),

2. 8664203 - Thiazole derivatives and their use as P2Y12 receptor antagonists (2014-03-04),

3. 8580824 - Pyridin-4-yl derivatives as immunomodulating agents (2013-11-12),

4. 8288554 - Pyridin-3-yl derivatives as immunomodulating agents (2012-10-16),

5. 8178562 - Pyridine derivatives (2012-05-15),

6. 8133910 - Thiophene derivatives as S1P1/EDGE1 receptor agonists (2012-03-13),

7. 8044076 - Phenyl derivatives and their use as immunomodulators (2011-10-25),

8. 8039644 - Hydrogenated benzo (C) thiophene derivatives as immunomodulators (2011-10-18),

9. 8003800 - Thiophene derivatives as S1P1/EDG1 receptor agonists (2011-08-23),

10. 7981924 - Thiophene derivatives (2011-07-19),

11. 7951794 - Thiophene derivatives (2011-05-31),

12. 7846964 - Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists (2010-12-07),

13. 7750040 - Thiophene derivatives (2010-07-06),

14. 7723378 - Hydrogenated benzo (C) thiophene derivatives as immunomodulators (2010-05-25),

15. 7605269 - Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists (2009-10-20),

Title: The Innovative Mind of David Lehmann: A Pioneer in Pharmaceutical Inventions

Introduction: David Lehmann, based in Basel, Switzerland, is a prominent inventor with a remarkable portfolio of 15 patents. His contributions to the field of pharmaceuticals have significantly impacted the development of therapies for various medical conditions. With a keen focus on creating novel pharmaceutical compounds, Lehmann's inventions address critical health challenges.

Latest Patents: Among his latest innovations, Lehmann has developed pyridine derivatives, which relate to novel compounds with significant immunosuppressive properties. These compounds show great promise in the field of medicine for their therapeutic uses. Another notable patent involves thiazole derivatives, designed as P2Y12 receptor antagonists, which play a vital role in treating and preventing various cardiovascular diseases associated with platelet aggregation. This invention highlights Lehmann’s commitment to addressing serious health issues through innovative solutions.

Career Highlights: Throughout his career, David Lehmann has established himself as a leading figure in pharmaceutical research and development. He has worked with notable companies, including Actelion Pharmaceuticals Ltd, where he contributed to the advancement of pharmaceutical technology and product innovation. His work is characterized by a dedication to enhancing drug efficacy and safety.

Collaborations: Lehmann has collaborated with talented colleagues in the industry, including Martin Bolli and Boris Mathys. These partnerships reflect the importance of teamwork in driving innovation and creating impactful medical solutions.

Conclusion: David Lehmann's inventive spirit and dedication to pharmaceutical research have made him a significant player in the field. With his latest patents promising to improve patient outcomes and broaden therapeutic options, Lehmann continues to exemplify the role of inventors in advancing healthcare. His work not only demonstrates personal achievement but also contributes to the broader community of medical innovation.

Profile summary based on public USPTO records.